相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pertuzumab: new hope for patients with HER2-positive breast cancer
M. Capelan et al.
ANNALS OF ONCOLOGY (2013)
Dual Blockade of HER2 in HER2-Overexpressing Tumor Cells Does Not Completely Eliminate HER3 Function
Joan T. Garrett et al.
CLINICAL CANCER RESEARCH (2013)
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
Sandra M. Swain et al.
LANCET ONCOLOGY (2013)
In Vivo Applications of Single Chain Fv (Variable Domain) (scFv) Fragments
Philippe P. Monnier et al.
ANTIBODIES (2013)
Novel anti-HER2 monoclonal antibodies: synergy and antagonism with tumor necrosis factor-α
Ceyhan Ceran et al.
BMC CANCER (2012)
Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors
Carmine Fedele et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Risk of rash with the anti-HER2 dimerization antibody pertuzumab: a meta-analysis
Aaron M. Drucker et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
New therapies in HER2-positive breast cancer: A major step towards a cure of the disease?
Ahmad Awada et al.
CANCER TREATMENT REVIEWS (2012)
scFv Antibody: Principles and Clinical Application
Zuhaida Asra Ahmad et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2012)
Antibody Phage Display Libraries: Contributions to Oncology
Carmela Dantas-Barbosa et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2012)
FDA approves pertuzumab
Cormac Sheridan
NATURE BIOTECHNOLOGY (2012)
Down-regulation of vascular endothelial growth factor expression by anti-her2/neu single chain antibodies
Foroogh Nejatollahi et al.
MEDICAL ONCOLOGY (2012)
Polyclonal HER2-specific antibodies induced by vaccination mediate receptor internalization and degradation in tumor cells
Xiu-Rong Ren et al.
BREAST CANCER RESEARCH (2012)
Resistance to HER2-directed antibodies and tyrosine kinase inhibitors
Joan T. Garrett et al.
CANCER BIOLOGY & THERAPY (2011)
Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers
Ritwik Ghosh et al.
CANCER RESEARCH (2011)
Production and Characterization of a Humanized Single-chain Antibody against Human Integrin αvα3 Protein
Dabin Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Rapid isolation of high-affinity human antibodies against the tumor vascular marker Endosialin/TEM1, using a paired yeast-display/secretory scFv library platform
Aizhi Zhao et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2011)
Structure-activity relationship of conformationally constrained peptidomimetics for antiproliferative activity in HER2-overexpressing breast cancer cell lines
Sashikanth Banappagari et al.
MEDCHEMCOMM (2011)
Lapatinib, a Dual EGFR and HER2 Kinase Inhibitor, Selectively Inhibits HER2-Amplified Human Gastric Cancer Cells and is Synergistic with Trastuzumab In vitro and In vivo
Zev A. Wainberg et al.
CLINICAL CANCER RESEARCH (2010)
Antibodies in Single-Chain Format Against Tumour-Associated Antigens: Present and Future Applications
L. Accardi et al.
CURRENT MEDICINAL CHEMISTRY (2010)
Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic Implications of Troponin I Evaluation
Daniela Cardinale et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy
Jose Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
The role of HER2 in cancer therapy and targeted drug delivery
Wanyi Tai et al.
JOURNAL OF CONTROLLED RELEASE (2010)
Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941
Teemu T. Junttila et al.
CANCER CELL (2009)
Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models
Werner Scheuer et al.
CANCER RESEARCH (2009)
Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity
M. Scaltriti et al.
ONCOGENE (2009)
HER2+breast cancer
David G. Hicks et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2008)
Cancer gene therapy of adenovirus-mediated anti-4-1BB scFv in immunocompetent mice
Fang Liu et al.
CANCER BIOLOGY & THERAPY (2008)
Drug therapy: Trastuzumab - Mechanism of action and use in clinical practice
Clifford A. Hudis
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Review: Side effects of approved molecular targeted therapies in solid cancers
Christian Widakowich et al.
ONCOLOGIST (2007)
HER2 therapy - Molecular mechanisms of trastuzumab resistance
Rita Nahta et al.
BREAST CANCER RESEARCH (2006)
Herceptin down-regulates HER-2/neu and vascular endothelial growth factor expression and enhances taxol-induced cytotoxicity of human Ewing's sarcoma cells in vitro and in vivo
H Guan et al.
CLINICAL CANCER RESEARCH (2005)
Structural analysis of the epitopes on erbB2 interacted with inhibitory or non-inhibitory monoclonal antibodies
JN Wang et al.
MOLECULAR IMMUNOLOGY (2004)
Untangling the ErbB signalling network
Y Yarden et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2001)
分享论文
